Immunology and inflammation

News

Amgen splashes out on ChemoCentryx and its blockbuster hopef...

Ten months after ChemoCentryx scored an unexpected FDA approval for autoimmune disease therapy Tavneos, Amgen has swooped in with a $3.7 billion bid to buy out the company.

News

Gilead snaps up MiroBio and its checkpoint agonists for $405...

Less than three years after being spun out of Oxford University, privately-held biotech MiroBio is heading for a takeover by Gilead Sciences in a $405 million deal.

News

Chinese biotech Sironax raises $200m for RIPK1 pipeline

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for

News

Reitsberger Hof Originalbild unter: http://xaver.fotograf.de/photo/5803d868-7d30-46c9-9bef-33690a5581f6

MorphoSys slims down, narrowing its focus to cancer

MorphoSys seemingly inexorable shift into an oncology pure-play has continued with an out-licensing deal for two programmes in the kidney disease and immunology categories to HIBio.

News

Open communication helps ulcerative colitis patients through COVID-19

Pfizer's Arena buyout looks canny, as etrasimod aces phase 3...

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceu

News

Dupixent claims new territory in eosinophilic oesophagitis

Sanofi and Regeneron have added another string to the bow of their immunology blockbuster Dupixent with an FDA approval in eosinophilic oesophagitis (EoE), which could help the drug reach i

Amgen splashes out on ChemoCentryx and its blockbuster hopef...

Gilead snaps up MiroBio and its checkpoint agonists for $405...

Chinese biotech Sironax raises $200m for RIPK1 pipeline

MorphoSys slims down, narrowing its focus to cancer

Pfizer's Arena buyout looks canny, as etrasimod aces phase 3...

Dupixent claims new territory in eosinophilic oesophagitis

FDA cites 'significant concerns' with ADC lymphoma trial

Discover a new era of healthcare panel engagement: Grounded ...

Immunology and inflammation

Editor's Picks